ArticlePharmaceuticals (Basel, Switzerland)2026
A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007).
Chenguang Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.